Review of siltuximab in the treatment of multicentric Castleman's disease.

Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood (1989) 4.17

Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (1990) 3.27

Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol (2014) 2.39

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 2.31

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02

Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med (1954) 1.85

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood (1991) 1.73

HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood (2014) 1.68

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res (2015) 1.53

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53

The clinical spectrum of Castleman's disease. Am J Hematol (2012) 1.41

Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist (2011) 1.40

Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist (2011) 1.26

Interleukin-6 as a therapeutic target. Clin Cancer Res (2015) 1.17

Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol (2001) 1.05

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther (2010) 1.00

Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma (2014) 0.89

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res (2015) 0.84

Siltuximab for multicentric Castleman disease. Expert Rev Hematol (2014) 0.83

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget (2015) 0.81

Siltuximab: first global approval. Drugs (2014) 0.81

Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am (2014) 0.80